The Effect of TENS on Pain and Analgesic Consumption After Total Hip Replacement.

Pain Manag NursJul 10, 2026 (epub)
Clinical ResearchOrthopedic SurgeryAnesthesiology

Açelya Türkmen, Ezgi Seyhan Ak, Ayşe Demirtaş et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of transcutaneous electrical nerve stimulation (TENS) on postoperative pain and analgesic use in 60 patients after total hip arthroplasty. The study found that pain scores were significantly lower in the TENS group compared to the control group (p < .001), although there was no significant difference in total analgesic consumption (p > .05).

Key findings

  • Postoperative pain scores were significantly lower in the TENS group compared to the control group (p < .001).
  • No significant difference in total analgesic consumption was observed between the groups (p > .05).

Why it matters

Understanding effective pain management strategies is crucial for improving patient outcomes after surgery. TENS may offer a noninvasive option to enhance comfort and reduce pain levels in the postoperative setting.

Source

PubMed · PMID 42425834

Published in Pain Manag Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.